RECURRENT MANTLE CELL LYMPHOMA
Clinical trials for RECURRENT MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: antibody combo targets cancer after CAR t fails
Disease control Recruiting nowThis phase II trial tests two antibodies, glofitamab and obinutuzumab, in 20 people with mantle cell lymphoma that has returned or not responded after CAR T-cell therapy. Glofitamab helps T cells attack cancer by binding to both T cells and lymphoma cells, while obinutuzumab bloc…
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to speed up treatment for blood cancer patients
Disease control Recruiting nowThis study tests a faster, hospital-based dose increase of the drug sonrotoclax for people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL) that is new, has returned, or hasn't responded to treatment. Participants first rece…
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New trial aims to bring targeted lymphoma drugs to minority patients
Disease control Recruiting nowThis phase 1 trial is testing a combination of two targeted drugs, zanubrutinib and sonrotoclax, in people from underrepresented racial and ethnic groups who have relapsed or refractory B-cell non-Hodgkin lymphoma. The study aims to see if this treatment is feasible and safe for …
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Experimental combo aims to outsmart resistant lymphoma
Disease control Recruiting nowThis early-phase trial tests whether combining two drugs—pacritinib and a BTK inhibitor—is safe and effective for people with mantle cell lymphoma that has come back or stopped responding to treatment. Ten adults will receive the combination and be monitored for side effects and …
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental CAR T-Cell combo aims to stop lymphoma relapse after transplant
Disease control Recruiting nowThis early-phase trial is testing whether giving special immune cells (CMV-specific CD19-CAR T cells) along with a vaccine (CMV-MVA triplex) after a stem cell transplant can safely help prevent B-cell non-Hodgkin lymphoma from returning. About 15 people with intermediate or high-…
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of CAR T-cell therapy called MC10029 for people with B-cell blood cancers that have returned or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in the lab to target a protein called …
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy aims to beat back tough lymphoma
Disease control Recruiting nowThis phase 2 trial tests a combination of two treatments for mantle cell lymphoma that has returned or is not responding to standard care. Patients receive their own immune cells that have been genetically modified to recognize and attack cancer cells (CAR-T cells), along with a …
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC